Special Issue "Epigenetics and Immune Checkpoints"
A special issue of Epigenomes (ISSN 2075-4655).
Deadline for manuscript submissions: closed (31 May 2021).
Interests: cancer epigenetics; immunotherapy
Interests: cancer epigenetics; ncRNAs; immunotherapy; targeted therapy
The epigenetic immune modeling of cancer cells represents a key hallmark of cancer, as it impairs the host’s functional immune recognition of malignant cells. The pharmacologic targeting of epigenetic alteration with epigenetic drugs has been demonstrated to possess significant immunomodulatory properties, sensitizing tumor cells to emerging immunotherapies.
Targeting immune checkpoint(s) with immunomodulatory monoclonal antibodies (mAbs) is a novel and rapidly evolving strategy to treat cancer, and is rapidly spreading to different tumor histologies.
Despite this unprecedented efficacy, a significant proportion of cancer patients do not achieve tumor regression due to primary resistance, or develop secondary resistance to anti-immune-checkpoint treatment over time.
Therefore, it is essential to identify new mechanism(s) underlying treatment failure(s) and design novel epigenetic-based combination therapeutic approaches to overcome primary/secondary resistance, in order to improve the overall efficacy of immune-checkpoint-blocking mAb therapy. In addition, novel biomarkers for the prediction of the response to immune-checkpoint inhibitors are urgently needed to stratify cancer patients who would benefit most from this treatment. In this context, epigenetic biomarkers would represent a valuable tool to predict response to immunotherapy, thus offering more personalized therapeutic regimens. Therefore, the aim of this Special Issue is to present a collection of the latest research regarding the role that epigenetics plays in improving cancer immunotherapy, and the utility that it offers in defining new potential therapeutic targets and cancer biomarkers.
Dr. Alessia Covre
Dr. Elisabetta Fratta
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epigenomes is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune-checkpoint inhibitors
- epigenetic therapies